Thrombosis in the Uremic Milieu-Emerging Role of "Thrombolome"

Seminars in Dialysis

Volumn 28, Issue 2, 2015, Pages 198-205

  Shashar, Moshe ^a   Francis, Jean ^a   Chitalia, Vipul ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; HEALTH; HUMAN; INCIDENCE; METABOLISM; METABOLOME; PHYSIOLOGY; RISK FACTOR; THROMBOSIS; UREMIA;

GLOBAL HEALTH; HUMANS; INCIDENCE; METABOLOME; RISK FACTORS; THROMBOSIS; UREMIA;

EID: 84924521482     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12255     Document Type: Article

References (88)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AYM, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 382:260-272, 2013
2. Couser WG, Remuzzi G, Mendis S, Tonelli M: The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258-1270, 2011
3. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
4. Shaw C, Pruthi R, Pitcher D, Fogarty D: UK Renal Registry 15th annual report: Chapter 2 UK RRT prevalence in 2011: national and centre-specific analyses. Nephron Clin Pract 123(Suppl):29-54, 2013
5. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2011. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2013
6. Mcdonald S, Hurst K: Australia and New Zealand Dialysis and Transplant Registry. ANZDATA Registry Report: Adelaide, South Australia, 2010
7. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36:S24-S30, 2000
8. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
9. Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M: Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 25:3296-3301, 2010
10. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR: Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19:135-140, 2008
11. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39:1011-1017, 2002
12. Ocak G, Verduijn M, Vossen CY, Lijfering WM, Dekker FW, Rosendaal FR, Gansevoort RT, Mahmoodi BK: Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 8:2428-2435, 2010
13. Lambert ND, Sacrinty MT, Ketch TR, Turner SJ, Santos RM, Daniel KR, Applegate RJ, Kutcher MA, Sane DC: Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 157:688-694, 2009
14. Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, Nanchal R: Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 7:1584-1590, 2012
15. Schoebel FC, Gradaus F, Ivens K, Heering P, Jax TW, Grabensee B, Strauer BE, Leschke M: Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography. Heart 78:337-342, 1997
16. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126-2130, 2005
17. Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T: Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the registry of stent thrombosis for review and reevaluation. Circulation 122:52-61, 2010
18. Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, Rogers EW, Breall JA, Lewis DH, Song A, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS: Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2:285-293, 2009
19. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HHT, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L: Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50:463-470, 2007
20. Riley RF, Don CW, Powell W, Maynard C, Dean LS: Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes 4:193-197, 2011
21. Cutlip DE, Baim DS, Ho KKL, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP, Chauhan MS, Rodriguez O, Kuntz RE: Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103:1967-1971, 2001
22. Motovska Z, Knot J, Widimsky P: Stent thrombosis-risk assessment and prevention. Cardiovasc Ther 28:e92-e100, 2010
23. Stähli BE, Camici GG, Tanner FC: Drug-eluting stent thrombosis. Ther Adv Cardiovasc Dis 3:45-52, 2009
24. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R: Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051-1058, 2007
25. Ting HH, Tahirkheli NK, Berger PB, McCarthy JT, Timimi FK, Mathew V, Rihal CS, Hasdai D, Holmes DR: Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 87(3):A9, 2001
26. The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment. USRDS. United States Renal Data System. Am J Kidney Dis 30(2 Suppl 1):S160-177, 1997
27. Mackman N: Triggers, targets and treatments for thrombosis. Nature 451:914-918, 2008
28. Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH: Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res 8:168-172, 2010
29. Furie B, Furie BC: Mechanisms of thrombus formation. N Engl J Med 359:938-949, 2008
30. Shlipak MG: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87-92, 2002
31. Segarra A, Chacón P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolomé J, Camps J, Moliner E, Pelegrí A, Marco F, Olmos A, Piera L: Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 12:1255-1263, 2001
32. Milburn JA, Ford I, Mutch NJ, Fluck N, Brittenden J: Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis. PLoS ONE 8:e67799, 2013
33. Sioulis A, Malindretos P, Makedou A, Makris P, Grekas D: Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients. Hippokratia 13:237-241, 2009
34. Gawaz MP1, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK: Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5(2):36-46, 1994
35. Aggarwal A, Kabbani SS, Rimmer JM, Gennari FJ, Taatjes DJ, Sobel BE, Schneider DJ: Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 40:315-322, 2002
36. Chiu JJ, Chen CN, Lee PL, Yang CT, Chuang HS, Chien S, Usami S: Analysis of the effect of disturbed flow on monocytic adhesion to endothelial cells. J Biomech 36:1883-1895, 2003
37. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R: The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol 9:439-453, 2012
38. Davies PF: Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 6:16-26, 2009
39. Malyszko J, Malyszko JS, Myśliwiec M: Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res 27:71-77, 2004
40. Nieuwdorp M, van Haeften TW, Gouverneur MCLG, Mooij HL, van Lieshout MHP, Levi M, Meijers JCM, Holleman F, Hoekstra JBL, Vink H, Kastelein JJP, Stroes ESG: Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55:480-486, 2006
41. Vlahu CA, Lemkes BA, Struijk DG, Koopman MG, Krediet RT, Vink H: Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 23:1900-1908, 2012
42. Salmon AHJ, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, Bates DO, Peti-Peterdi J: Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 23:1339-1350, 2012
43. Serradell M, Díaz-Ricart M, Cases A, Zurbano MJ, López-Pedret J, Arranz O, Ordinas A, Escolar G: Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. Haematologica 87:1053-1061, 2002
44. Gondouin B, Cerini C, Dou L, Sallée M, Duval-sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 84(4): 733-744, 2013
45. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H: Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 62:1757-1763, 2002
46. Amabile N, Guérin AP, Tedgui A, Boulanger CM, London GM: Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 27:1873-1880, 2012
47. Mackman N: Uremic serum and ubiquitylation of tissue factor. Circulation 127:320-321, 2013
48. Keller C, Katz R, Cushman M, Fried LF, Shlipak M: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9:9, 2008
49. Zieman SJ, Melenovsky V, Kass DA: Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25:932-943, 2005
50. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL: Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13:1086-1095, 2007
51. Zhang RY, Zhu ZB, Zhang Q, Yang ZK, Hu J, Lv AK, Zhang JS, Shen WF: Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol 136:72-79, 2009
52. Miao Y, Yu-Jie Z, Zhi-Jian W, Dong-Mei S, Yu-Yang L, Ying-Xin Z, Fei G, Shi-Wei Y, De-An J: Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv 80:361-367, 2012
53. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 299:2164-2171, 2008
54. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 84:733-744, 2013
55. Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, Edelman ER: Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 127:365-376, 2013
56. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63:1934-1943, 2003
57. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23:1258-1270, 2012
58. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins-update 2009. Semin Dial 22:334-339, 2009
59. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 76:S12-S19, 2009
60. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, Eloot S, Rops A, Vande Voorde J, De Vriese A, van der Vlag J, Brunet P, Van Biesen W, Vanholder R: Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol 24(12):1981-1994, 2013
61. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 23:1211-1221, 2008
62. Moroni F: Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 375:87-100, 1999
63. Niwa T: Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 72:1-11, 2010
64. Alfred F, Drummond KN, Doeden D, Good RA: Tryptophan metabolism in man. J Clin Invest 43:1730-1746, 1964
65. Banoglu E, Jha GG, King RS: Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet 26:235-240, 2001
66. Sims J, Renwick AG: The microbial metabolism of tryptophan in rats fed a diet containing 7.5% saccharin in a two-generation protocol. Food Chem Toxicol 23:437-444, 1985
67. Deguchi T, Ohtsuki S, Otagiri M, Takanaga H, Asaba H, Mori S, Terasaki T: Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 61:1760-1768, 2002
68. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y: Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174, 2004
69. Pawlak K, Mysliwiec M, Pawlak D: Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 102:49-55, 2009
70. Pawlak K, Myśliwiec M, Pawlak D: Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci 55:196-203, 2010
71. Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, Takita T, Furuhashi M, Maruyama Y, Chida K, Hishida A: Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 14:418-424, 2010
72. Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, Naesens M, Vanrenterghem Y, Kuypers D, Evenepoel P, Meijers B: Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 8:1508-1514, 2013
73. Meijers BKI, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54:891-901, 2009
74. Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Halperin JL, Robbins MJ: Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 72:365-373, 2005
75. Undas A, Bro J, Szczeklik A: Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 94(5):907-915, 2005
76. Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T: Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol 65:97-102, 2006
77. Saifan C, El-Charabaty E, El-Sayegh S: Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. Vasc Health Risk Manag 9:361-364, 2013
78. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. JAMA 298(10):1163-1170, 2007
79. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W: A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104:1292-1295, 2009
80. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14:2313-2321, 2003
81. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 13:2331-2337, 2002
82. Lekawanvijit S, Kumfu S, Wang BH, Manabe M, Nishijima F, Kelly DJ, Krum H, Kompa AR: The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS ONE 8:e83687, 2013
83. Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TTY, Lee YT, Liao SC: Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purif 37:76-83, 2014
84. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS: p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 26:938-947, 2011
85. Huang ST, Shu KH, Cheng CH, Wu MJ, Yu TM, Chuang YW, Chen CH: Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients. Transplant Proc 44:621-624, 2012
86. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4:1551-1558, 2009
87. Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, Chen HH, Wu CJ: Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 43:451-456, 2012
88. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ: p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 25:191-197, 2011